Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Selective induction of DeltaFosB in the brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of DeltaFosB and galectin-1 in neuroprotection and neurogenesis
KLOW, BPC-157, TB-500, KPV and GHK-Cu are not FDA-approved treatments for injury recovery, inflammation, digestive disorders, skin rejuvenation, hair growth, anti-aging or general wellness
Human side-effect rates and interaction risks are not established
Exploratory endpoints included achieving 15% and 20% weight loss, and patient-reported outcomes assessed using the SF-36 v2.0 and the Three-Factor Eating Questionnaire (TFEQ-R18 v2)
In vitro studies demonstrate that BPC-157 promotes survival of cells exposed to various stressors including oxidative damage, toxic substances, and serum deprivation
CG189: Obesity: identification, assessment and management
